Once regarded as one of Europe's most promising biotechs, the curtain has fallen on Oxurion NV after the last diabetic eye disease drug in its pipeline failed a mid-stage trial.
The Belgian ophthalmology specialist said on 20 November it had "decided to take the necessary steps to file for bankruptcy"...